US20180056569A1 - Bioabsorbable polymeric composition and medical device - Google Patents

Bioabsorbable polymeric composition and medical device Download PDF

Info

Publication number
US20180056569A1
US20180056569A1 US15671050 US201715671050A US2018056569A1 US 20180056569 A1 US20180056569 A1 US 20180056569A1 US 15671050 US15671050 US 15671050 US 201715671050 A US201715671050 A US 201715671050A US 2018056569 A1 US2018056569 A1 US 2018056569A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
step
method
lactide
accord
polymer composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US15671050
Inventor
Robert J. Cottone
G. Lawrence Thatcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orbus Medical Technologies Inc
Original Assignee
Orbus Medical Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE, IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C47/00Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C47/0009Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the articles
    • B29C47/0026Hollow flexible articles, e.g. blown foils or films
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/041Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/048Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148Materials at least partially resorbable by the body
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE, IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C47/00Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C47/0004Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the choice of material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A61F2002/9155Adjacent bands being connected to each other
    • A61F2002/91591Locking connectors, e.g. using male-female connections
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0028Shapes in the form of latin or greek characters
    • A61F2230/0054V-shaped
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE, IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS
    • B29K2067/00Use of polyesters or derivatives thereof as moulding material
    • B29K2067/04Polyesters derived from hydroxycarboxylic acids
    • B29K2067/046PLA, i.e. polylactic acid or polylactide
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE, IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS
    • B29K2995/00Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037Other properties
    • B29K2995/0059Degradable
    • B29K2995/006Bio-degradable, e.g. bioabsorbable, bioresorbable or bioerodible
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE, IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS
    • B29K2995/00Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037Other properties
    • B29K2995/0088Molecular weight
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE, IN GENERAL
    • B29LINDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00Other particular articles
    • B29L2031/753Medical equipment; Accessories therefor
    • B29L2031/7532Artificial members, protheses

Abstract

A method for fabricating an embodiment of a medical device comprising the steps of: preparing a biodegradable polymeric structure; coating the biodegradable polymeric structure with a polymeric coat including a pharmacological or biological agent; cutting the structure into patterns configured to allow for crimping of the cut structure and expansion of the cut structure after crimping into a deployed configuration.

Description

    BACKGROUND
  • All references cited in this specification, and their references, are incorporated by reference herein in their entirety where appropriate for teachings of additional or alternative details, features, and/or technical background.
  • The invention relates to a medical device for implantation into vessels or luminal structures within the body. In one embodiment, the present invention relates to stents and synthetic grafts which are coated with a controlled-release matrix comprising a medicinal substance for direct delivery to the surrounding tissues, which may include a ligand attached thereto for capturing progenitor endothelial cells in the blood contacting surface of the device to form mature, functional, endothelium at site of injury. In particular, the polymer matrix/drug/ligand-coated devices such as stents are for use, for example, in therapy of diseases and conditions such as restenosis, artherosclerosis, and endoluminal reconstructive therapies.
  • Disclosed in embodiments herein is a novel tube-shaped expandable scaffold configured to fit within the vasculature, including the cardiovasculature, having a low, propensity for biological rejection. Such scaffold may consist of, or comprise, a bioabsorbable polymer composition or blend that effectuates a combination of mechanical properties balancing elasticity, rigidity and flexibility. The polymer composition may include a base material including a bioabsorbable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive. Advantageously the polymer may be selected to undergo enzymatic degradation and absorption. In particular, the composition may allow for a “soft” breakdown mechanism allowing for the breakdown of the component polymers to be less injurious to the surrounding tissue.
  • A persistent problem associated with the use of metallic devices such as stents is found in the formation of scar tissue coating of the vascularly located stent, the so-called process of restenosis. Many have concluded that the continued risk of stent thrombosis due to the permanent aspect of metal stents has not been overcome by coating of the metal with drugs intended to prevent such calamities. On the contrary, an increase in death rate has also been associated with a number of these coatings. Moreover, metallic and polymeric stents may prevent vascular lumen remodeling and expansion.
  • With respect to stents, stents may prevent the healing of tissue and reduce complement activation of the immune response. Stents have also been associated in some instances with a reduced inflammatory response and trauma upon break-up of an implant and/or its component materials. Conventional stents may also not provide a desired degree of flexibility in shape allowing for easier implantation, particularly into blood vessels.
  • The present inventors have recognized a need to develop medical devices such as stents and vascular synthetic grafts, manufactured from biocompatible, biodegradable bioabsorbable polymer blends as base polymer which are useful for the treatment of disease, in particular of the vascular system. The medical devices may ameliorate problems associated with present devices.
  • As disclosed herein, it has been recognized by the present inventors that the base polymer may be selected to allow additional molecular free volume to encourage sufficient molecular motion so as to allow for re-crystallization to occur at physiological conditions (e.g., upon the addition of molecular strain). Increased molecular free volume may allow for an increase in the rate of water uptake adding both a plasticizing effect as well as increasing the bulk degradation kinetics.
  • In embodiments herewith, the compositions allow for a “soft” breakdown mechanism such that the breakdown proceeds while being friendly to the surrounding tissue (less inflammatory response, and rendering lower potential for trauma upon break up of an implant). By selecting a polymer or copolymer having an enhanced hydrophilic property for either the base or the additive or both, the polymer blend may reduce complement activation and minimize or prevent opsonization.
  • In certain embodiments, the bioabsorbable scaffolds allow flexibility and stretchability suitable for the implantation in the pulse movements, contractions and relaxations of, for example, the cardiovascular system.
  • REFERENCES
  • Reference is made to U.S. Pat. No. 6,607,548 B2 (Inion), issued Aug. 19, 2003, which discloses biocompatible and bioresorbable compositions comprising a lactic acid or glycolic acid based polymer or copolymer blended with one or more copolymer additives. Such implants are asserted to be cold-bendable without crazing or cracking. Reference is also made to EP 0401844, which discloses a blend of poly-L-lactide with poly D-DL-lactide, and U.S. Pat. No. 6,001,395 which discloses drug delivery with lamellar particles of a biodegradable poly(L-lactide) or copolymers or blends thereof, being at least in part crystalline. U.S. Pat. No. 7,070,607 discloses an aneurysm repair coil comprising a bioabsorbable polymeric material carrying an embolic agent wherein the thrombogenicity is controlled by the polymer composition.
  • SUMMARY
  • Embodiments disclosed herein are method of manufacturing bioabsorbable medical devices, such as stents and synthetic grafts comprising a bioabsorbable polymer composition. The medical devices are biocompatible, biodegradable and can deliver mechanical support as well as pharmaceutical substances to an injured organ after implantation into a patient.
  • In one embodiment, the medical devices are configured to encapsulate therapeutic agents within the walls of their structure for the treatment of diseases such as artherosclerosis, restenosis and the like. In one embodiment, as the bioabsorbable device breaks down, the device provides controlled released of the pharmaceutical trapped within its wall or integrally part of the polymeric composition. In this and other embodiments, pharmaceutical substances can be covalently attached or admixed to the polymeric material comprising the medical device. In certain embodiments, the medical device may have a coating for stimulating restoration of normal endothelium at the site of implant.
  • In one embodiment, there is provided a method for the manufacturing of a polymeric medical device with a coating. The method comprises the making of a polymeric medical device from a bioabsorbable polymeric composition comprising a base polymer which can be a crystallizable polymer. The method comprises making a crystallizable polymeric composition; forming a structure such as a structure which is the form of a medical device, for example, a stent; coating said structure in its luminal surface with one or more layers of a composition comprising a polymeric matrix and with or without one or more pharmaceutical substance and a ligand for recognizing and binding to target cells in the circulation. The method further comprises the step of coating the medical structure in an opposing surface, in the case of a stent, coating the abluminal surface with a composition comprising the same or different pharmaceutical substance for local delivery to the surrounding tissue.
  • In one embodiment, the method of manufacturing further comprises the step of designing and cutting the polymer device to a specific structure prior to coating the device or after coating the device. In this embodiment, the pharmaceutical substance and compositions comprising the coating can be applied prior to designing and cutting the device structure, or after the device is coated.
  • In one embodiment, there is disclosed a cardiovascular tube-shaped expandable scaffold such as a stent, fabricated from a bioabsorbable polymer composition or blend having a combination of mechanical properties balancing elasticity, rigidity and flexibility allowing bending and crimping of the scaffold tube onto an expandable delivery system (such as a balloon catheter) which is attached to a suitable vascular lumen insertion means. The deployed scaffold may be expanded from a narrowly crimped delivery conformation to a lumen diameter sufficient for implantation onto the vascular wall tissue. The flexible form of a polymer scaffold may also afford the capability of overstretching its configuration so as to facilitate insertion into blood vessel with minimal vessel wall contact. In addition, the scaffold can be manipulated to vary from a cylindrical to a truncated conical shape allowing for easy implant installation, relocation, and adjustment.
  • In one embodiment, the medical device is provided in an expandable scaffold, which provides a crimpable and expandable structure without stress crazing. In embodiments wherein the medical device is a stent, the expandable scaffold provides a set of interlocking struts for stabilizing the device in its deployed or expanded or implanted conformation.
  • Another embodiment of the scaffold polymer provides enhanced mechanical properties through a molecular reorientation and crystallization during the radial strain of expansion from a crimpable state to an expanded state.
  • In one embodiment, the medical device is provided as a scaffold implant in a delivery system comprising a catheter adapted with a balloon type reversible inflation or dilation means. In one embodiment, a balloon inflating device may be employed which may be heated or cooled.
  • In an alternate embodiment, the medical device is provided with a polymer breakdown moieties that are “friendly” at the contact vascular wall area. In certain embodiments, the breakdown kinetics are sufficiently slow to avoid tissue overload or other inflammatory reactions.
  • In one embodiment there is provided a minimum of 30-day retention of clinically supportive strength that may endure in place, for example, about 3-4 months. Evaluation criteria for such embodiment scaffolds may be based, for example, on mass loss in terms of decreased molecular weight, retention of mechanical properties, and tissue reaction.
  • In alternate embodiments, the medical device comprising a expandable scaffold is operably configured to change to from a solid state to a “rubbery state,” allowing for easier surgical intervention. In this embodiment, the rubbery state of the device is attained one the device is in physiological conditions in vivo.
  • Optionally the polymers and construction of the device may be selected to have flexibility and elasticity suitable for an implant in friction-free contact with vascular walls during the cardiovascular pulsing contractions and relaxations.
  • Preferably the scaffold in an embodiment is stretchable and elastic but has a sufficiently rigid strength to be capable of withstanding the cardiovascular fluctuating pressures within a blood vessel.
  • According to an embodiment, the bioabsorbable polymer is composed of a poly(L-lactide) or a poly(D-lactide) base polymer. Modifying copolymers include poly L(or D)-lactide-co-Tri-methylene-carbonate or poly-L(or D)-lactide-co-e-caprolactone may be used to link the base polymers. These copolymers can be synthesized as block copolymers or as “blocky” random copolymers wherein the lactide chain length is sufficiently long enough to crystallize. The development of a crystalline morphology may enhance the mechanical properties of the medical device; enhance processing conditions, and provide the potential of cross-moiety crystallization, for example, thermal cross-links. In this embodiment, the polymer composition allows the development of the lactide racemate crystal structure, between the L and D moieties, to further enhance the mechanical properties of the medical device.
  • It is also envisioned that the degradation time of the polymer in the composition may be shortened by enhancing degradation kinetics. For example, the starting material may be a lower molecular weight composition and/or a base polymer may be employed that is more hydrophilic or liable to hydrolytic chain scission.
  • According to embodiments of the invention there is provided a compositions and methods for fabricating a base copolymer having one moiety, such as L-lactide or D-lactide, is sufficiently long enough and not sterically hindered to crystallize, with a lesser moiety, for example Glycolide or Polyethylene Glycol (PEG) or monomethoxy-terminated PEG (PEG-MME).
  • The compositions, in addition to the base polymer, the modifying polymer or co-polymer, may include other materials and compounds that enhance degradation kinetics such as e-caprolactone copolymer moiety, wherein the caprolactone remains amorphous with resulting segments more susceptible to hydrolysis. Such compositions may be manufactured, for example, by admixing with the base polymer blend, or reacting to the base polymer.
  • The composition may incorporate PEG copolymers, for example either AB diblock or ABA triblock with the PEG moiety being approximately 1%. The mechanical properties of the lactide (see Enderlie and Buchholz SFB May 2006) may be maintained. The incorporation of either PEG or PEG-MME copolymers may also be used to facilitate drug attachment to the polymer, for example in conjunction with a drug eluting medical device.
  • Another embodiment provides a scaffold base polymer combining polymers of low PEG content of less than 5% in high MW, i.e., 2-3 IV copolymers, which enables the lactide block to crystallize and impart equivalent strength to the base polymer.
  • The scaffold of embodiments herein may provide a polymer core material containing at least one encapsulated drug for localized treatment of the vascular wall and lumen. The scaffold core degradation schedule may provide, for example, a simultaneously slow release of medication for the treatment and prevention of tissue inflammation and platelet aggregation.
  • Another embodiment of the polymer composition or blend provides uniform degradation in situ avoiding polymer release in chunks. The scaffold may carry at least one attached or embedded identification marker made from a radioopaque material.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates a representative bioabsorbable stent design.
  • FIG. 2 is a photograph of a representative bioabsorbable stent device.
  • FIG. 3A and FIG. 3B are photographs of bioabsorbable stents comprising poly(L-Lactic) acid.
  • FIG. 4A illustrates a bioabsorbable stent design comprising stabilizing interlocking mechanism.
  • FIG. 4B illustrate a bioabsorbable stent design mounted on a balloon catheter and also showing the interlocking mechanisms at the free ends.
  • FIG. 5A and FIG. 5B illustrate a bioabsorbable stent design comprising stabilizing interlocking mechanism at the ends.
  • FIG. 6 illustrates a bioabsorbable stent design depicting a folded ring segment.
  • FIG. 7 illustrates a bioabsorbable stent design depicting a ring segment.
  • FIG. 8 illustrates a bioabsorbable stent design depicting a fully expanded diameter.
  • FIG. 9A and FIG. 9B illustrate a bioabsorbable stent struts design depicting a the direction of stress points on the components of the scaffold.
  • FIG. 10A and FIG. 10B illustrate an embodiment of a bioabsorbable stent design.
  • FIG. 11A illustrates a bioabsorbable stent design depicting a folded ring segment and the ring segment in its open configuration. FIG. 11B shows the stent design from an alternate angle.
  • FIG. 12A and FIG. 12B illustrate an alternate bioabsorbable stent design depicting a ring segment in different states.
  • FIG. 13 and FIG. 14 illustrate bioabsorbable stent designs depicting the configuration of the wall of a stent and its segments.
  • FIG. 15 illustrates a bioabsorbable stent design comprising a radiopaque marker integrated within the stent wall.
  • FIG. 16 illustrates a bioabsorbable stent design depicting a the average body collapse pressure. (Average body collapse pressure: (1) PLLA E2 R-stent (n=3): 4.5 psi (SD 0.3 psi); (2) PLLA CoCr R-stent (n=3): 2.7 psi (SD 0.4 psi). Upon removal of pressure, all crushed stents recovered 40+% of lumen diameter.)
  • FIG. 17 is a bar graph illustrating data depicting the radial strength of bioabsorbable stents.
  • FIG. 18 illustrates is a bar graph illustrating data depicting the percent material of bioabsorbable stents expanded in blood vessels.
  • FIG. 19 is a bar graph illustrating data depicting percent stent recoil.
  • FIG. 20 illustrates a schematic representation of a bioabsorbable stent strut in cross section, which comprises a stent configuration having encapsulated pharmaceutical composition within the struts. In this embodiment, the stent is coated with a matrix comprising an antibody coating and a drug-coated abluminal surface of the device. (Program goal to produce a biodegradeable, Abluminal Focused Drug Eluting (RxTBD), Coated Platform. Should the Rx(s) component be integral throughout?)
  • DETAILED DESCRIPTION
  • Polymer compositions of the present invention may be used to manufacture medical device for implantation into a patient. The medical devices are scaffolds having biodegradable, bioabsorbable properties and include, but are not limited to, stents, stent grafts, vascular synthetic grafts, catheters, shunts, vascular shunts, valves, grafts and the like.
  • The invention is also directed to methods of making the biodegradable polymer compositions and methods for making the medical devices from the polymer compositions disclosed herein.
  • In one embodiment, the medical device comprises a crimpable polymeric stent, which can be inserted onto a balloon delivery system for implantation. The balloon may comprise a thermal balloon or non-thermal balloon. The medical device can have a structure which is crimpable during loading and expandable without stress under physiological conditions. The medical device may comprise a structure that comprises polymers that which can orient and/or crystallize upon strain of deployment, for example during balloon dilation, in order to improve the medical devices mechanical properties. By employing a medical device comprising polymers having slow breakdown kinetics one may avoid tissue overload or other inflammatory responses at the site of implantation.
  • The medical devices of the invention, can be structurally configured to provide the ability to change and conform to the area of implantation and to allow for the normal reestablishment of local tissues. The medical devices can transition from solid to a “rubbery state” allowing for easier surgical intervention, than, for example a stainless steel stent. A medical device may be designed to have, for example, a minimum of 30-day retention of clinically sufficient strength.
  • In one embodiment, the medical device is comprised of a polymer composition can comprise a base polymer which can be present from about 60% to about 95% by weight, or from about 70% to about 80% by weight of the composition. For example, the polymer formulation can comprise from about 70% by weight poly L-lactide (about 1.5 to 3.5 or from about 2.5 to 3 IV) with the poly L-lactide-co-TMC(80/20 w/w) (1.0 to 2.6 IV or from about 1.4 to 1.6 IV).
  • In another embodiment, the polymer formulation comprises 70% by weight triblock poly L-lactide-co-PEG(95/5 to 99/01, or from about 98/2 to 99/01) (2,000 to 100 Mw PEG, or 6,000 to 8000 Mw PEG) with the poly L-lactide-co-TMC(70/30) (1.4 to 1.6 IV). The polymer composition may also comprise a formulation of about 70% by weight diblock poly L-lactide-co-PEG-MME(95/05 to 99/01) (2,000 to 100 Mw PEG-MME, or 6,000 to 8000 Mw PEG-MME) with poly L-lactide-co-TMC(70/30 w/w) (1.4 to 1.6 IV).
  • Pharmaceutical compositions may be incorporated with the polymers by for example grafting to the polymer active sites, impregnating or encapsulating within the polymer composition prior to forming the medical device so as to integrate the composition within the walls of the device and/or coating the medical device one formed on the surface of the device, in particular the abluminal surface.
  • In embodiments disclosed herein, the medical device comprises a stent, which is structurally configured to be deployed into, for example, an artery or a vein, and be able to expand in situ, and conform to the blood vessel lumen the stent may be used to reestablish blood vessel continuity at the site of injury. The stent can be configured to have many different arrangements so that it is crimpable when loading, and expandable and flexible at physiological conditions once deployed. The biodegradable medical device may comprise a base polymer comprising, for example ply L-Lactide or poly D-Lactide, modifying co-polymer(s), such as poly L(or D) lactide-co-Tri-methylene-carbonate or poly L(or D)-lactide-co-e-caprolactone, as described above.
  • Various embodiments of biodegradable polymeric stents, and/or stent walls with different configuration are illustrated in FIGS. 1-15. For example, the stent is a tubular structure comprising struts operably designed to allow blood to traverse its walls so that the adjacent tissues are bathed or come in contact with it as blood flows through the area. The particular stent designs selected may depend on the size of the stent radially and longitudinally. FIG. 11A illustrates a scaffold wherein a number of looped structures are positioned above a collapsable/expandable suspension strut as illustrated in FIG. 11A the looped structures a . . . an expand along an axis and suspension strut b is expanded along the same axis. Suspension strut b may be constructed so as to form a closed loop, such as a circumferential loop as shown at FIGS. 11A and 11B; and FIG. 12A and FIG. 12B. The cross-linking strut of the unrolled scaffold of FIG. 11 a may maintain higher loop strength. FIG. 15 shows a tube structure embodiment employing such technology; other shapes such as conical, or bifurcated, are also envisioned.
  • Scaffolds of the present inventions may find employment in many biological areas including, without limitation, the trachea, bracial, fallopian tube, esophagous, and vasculature. Scaffolds may comprise or may be coated with, any type of drug such as hormones, serp-1, MPA etc.
  • Scaffold elements may be configured to prematurely deform to their maximum length and/or structure and then plastically elongate to form or create a second structure within which has different mechanical properties when compared to the primary structure of the composite structure. Over stretching of the structure may be advantageous to enable alignment of crystalline structures, thereby increasing structural strength. The secondary structure within the primary structure may allow, for example, a bifurcated shape. The secondary structure would allow changes in structures beyond that allowed by simple plastic deformation.
  • A method of the invention comprises a method for making a bioabsorbable polymeric implant comprising: (a) blending a polymer composition comprising a crystallizable composition comprising a base polymer of poly L-lactide or poly D-lactide linked with modifying copolymers comprising poly L(or D)-lactide-co-Tri-methylene-carbonate or poly L(or D)-lactide-co-e-caprolactone in the form of block copolymers or as blocky random copolymers wherein the lactide chain length is sufficiently long enough to allow cross-moiety crystallization; (b) molding said polymer composition to structurally configure said implant; and (c) cutting said implant.
  • In one embodiment, the blended form is molded in the faint of a tube defining a lumen therein. The tube may then be cut using laser, air knife, or mechanical means, or the like, to faun the desired design, such as a stent scaffold. In another embodiment, the blended form is molded into sheets. The sheets are then cut using a laser, air knife, or mechanical means, or the like, to the desired design. If desired, the designed cut sheet may then be welded, annealed, engaged, etc. with another portion of the sheet to form the overall structure desired. For example, the designed, cut, sheet may be rolled into a tubular form and welded along a seam, forming a tube that may later be cut into stents, etc. The sheet itself may be coated on one or both sides with a material, in particular a composition comprising a biological or pharmacological agent. One side may have a coating formed of a different matrix and/or different biological or pharmacological agent or agents.
  • A method for fabricating the medical device may comprise: (a) preparing a biodegradable polymeric structure; (b) designing said polymeric structure to be configured to allow for implantation into a patient; (c) cutting said structure into patterns configured to permit traversing of the device through openings and to allow for crimping of the device.
  • The medical device of the invention can be any device used for implanting into an organ or body part comprising a lumen, and can be, but is not limited to, a stent, a stent graft, a synthetic vascular graft, a heart valve, a catheter, a vascular prosthetic filter, a pacemaker, a pacemaker lead, a defibrillator, a patent foramen ovale (PFO) septal closure device, a vascular clip, a vascular aneurysm occluder, a hemodialysis graft, a hemodialysis catheter, an atrioventricular shunt, an aortic aneurysm graft device or components, a venous valve, a sensor, a suture, a vascular anastomosis clip, an indwelling venous or arterial catheter, a vascular sheath and a drug delivery port. The medical device can be made of numerous bioabsorbable materials depending on the device, biodegradable materials such as polylactide polymers and polyglycolide polymers or copolymers thereof are the most suitable.
  • In one embodiment, the medical device comprises a coating comprising a matrix which comprises a nontoxic, biocompatible, bioerodible and biodegradable synthetic material. The coating may further comprise one or more pharmaceutical substances or drug compositions for delivering to the tissues adjacent to the site of implantation, and one or more ligands, such as a peptide, small and/or large molecules, and/or antibodies or combinations thereof for capturing and immobilizing progenitor endothelial cells on the blood contacting surface of the medical device.
  • In one embodiment, the implantable medical device comprises a stent with a coating. In accordance with one embodiment, the stent is an expandable intraluminal endoprosthesis designed and configured to have a surface for attaching a coating for controlled or slow release of a therapeutic substance to adjacent tissues.
  • In one embodiment, the controlled-release matrix can comprise one or more polymers and/or oligomers from various types and sources, including, natural or synthetic polymers, which are biocompatible, biodegradable, bioabsorbable and useful for controlled-released of the medicament. For example, in one embodiment, the naturally occurring polymeric materials can include proteins such as collagen, fibrin, tropoelastin, elastin, cross-linked tropoelastin and extracellular matrix component, or other biologic agents or mixtures thereof. In this embodiment of the invention, the naturally-occurring material can be made by genetic engineering techniques from exogenous genes carried by vectors, such as a plasmid vector and engineered into a host, such as a bacterium. In this embodiment, desired polymer proteins such as tropoelastin and elastin can be produced and isolated for use in the matrix. In alternate embodiments, the naturally occurring polymeric matrices can be purified from natural sources by known methods or they can be obtained by chemical synthesis of the protein polymer. In certain embodiments, the naturally occurring material can be chemically modified or synthesized, for example, by cross-linking the material such as proteins, or by methylation, phosphorylation and the like. In another embodiment, the matrix can comprise a denuded blood vessel or blood vessel scaffolds and/or components thereof.
  • In one embodiment, the matrix may comprise a synthetic material which can include polyesters such as polylactic acid, polyglycolic acid or copolymers and or combinations thereof, a polyanhydride, polycaprolactone, polyhydroxybutyrate valerate, polydixanone, and other biodegradable polymer, or mixtures or copolymers thereof. In this embodiment, the matrix comprises poly(lactide-coglycolide) as the matrix polymer for coating the medical device. In this embodiment, the poly(lactide-co-glycolide) composition comprises at least one polymer of poly-DL-co-glycolide or copolymer or mixtures thereof, and it is mixed together with the pharmaceutical substances to be delivered to the tissues. The coating composition is then applied to the surface of the device using standard techniques such as spraying, dipping, and/or chemical vaporization. Alternatively, the poly(lactide-co-glycolide) (PGLA) solution can be applied as a single layer separating a layer or layers of the pharmaceutical substance(s).
  • In another embodiment, the coating composition further comprises pharmaceutically acceptable polymers and/or pharmaceutically acceptable carriers, for example, nonabsorbable polymers, such as ethylene vinyl acetate (EVAC) and methylmethacrylate (MMA). The nonabsorbable polymer, for example, can aid in further controlling release of the substance by increasing the molecular weight of the composition thereby delaying or slowing the rate of release of the pharmaceutical substance.
  • In certain embodiments, the polymer material or mixture of various polymers can be applied together as a composition with the pharmaceutical substance on the surface of the medical device and can comprise a single layer. Multiple layers of composition can be applied to form the coating. In another embodiment, multiple layers of polymer material or mixtures thereof can be applied between layers of the pharmaceutical substance. For example, the layers may be applied sequentially, with the first layer directly in contact with the uncoated surface of the device and a second layer comprising the pharmaceutical substance and having one surface in contact with the first layer and the opposite surface in contact with a third layer of polymer which is in contact with the surrounding tissue. Additional layers of the polymer material and drug composition can be added as required, alternating each component or mixtures of components thereof.
  • In another embodiment, the matrix may comprise non-polymeric materials such as nanoparticles formed of, for example, metallic alloys or other materials. In this embodiment, the coating on the medical device can be porous and the pharmaceutical substances can be trapped within and between the particles. In this embodiment, the size of the particles can be varied to control the rate of release of the pharmaceutical substance trapped in the particles depending on the need of the patient. In one embodiment, the pharmaceutical composition can be a slow/controlled-release pharmaceutical composition.
  • Alternatively, the pharmaceutical substance of the coating can be applied as multiple layers of a composition and each layer can comprise one or more drugs surrounded by polymer material. In this embodiment, the multiple layers of pharmaceutical substance can comprise a pharmaceutical composition comprising multiple layers of a single drug; one or more drugs in each layer, and/or differing drug compositions in alternating layers applied. In one embodiment, the layers comprising pharmaceutical substance can be separated from one another by a layer of polymer material. In another embodiment, a layer of pharmaceutical composition may be provided to the device for immediate release of the pharmaceutical substance after implantation.
  • In one embodiment, the pharmaceutical substance or composition may comprise one or more drugs or substances which can inhibit smooth muscle cell migration and proliferation at the site of implantation, can inhibit thrombus formation, can promote endothelial cell growth and differentiation, and/or can inhibit restenosis after implantation of the medical device. Additionally, the capturing of the progenitor endothelial cells on the luminal surface of the medical device accelerates the formation of a functional endothelium at the site of injury.
  • Examples of compounds or pharmaceutical compositions which can be incorporated in the matrix, and/or impregnated into the medical device include, but are not limited to prostacyclin, prostacyclin analogs, α-CGRP, α-CGRP analogs or α-CGRP receptor agonists; prazosin; monocyte chemoattactant protein-1 (MCP-1); immunosuppressant drugs such as rapamycin, drugs which inhibit smooth muscle cell migration and/or proliferation, antithrombotic drugs such as thrombin inhibitors, immunomodulators such as platelet factor 4 and CXC-chemokine; inhibitors of the CX3CR1 receptor family; antiinflammatory drugs, steroids such as dihydroepiandrosterone (DHEA), testosterone, estrogens such as 17β-estradiol; statins such as simvastatin and fluvastatin; PPAR-alpha ligands such as fenofibrate and other lipid-lowering drugs, PPAR-delta and PPAR-gamma agonists such as rosiglitazone; PPAR-dual-αγ agonists, LBM-642, nuclear factors such as NF-κβ, collagen synthesis inhibitors, vasodilators such as acetylcholine, adenosine, 5-hydroxytryptamine or serotonin, substance P, adrenomedulin, growth factors which induce endothelial cell growth and differentiation such as basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), endothelial cell growth factor (EGF), vascular endothelial cell growth factor (VEGF); protein tyrosine kinase inhibitors such as Midostaurin and imatinib or any anti-angionesis inhibitor compound; peptides or antibodies which inhibit mature leukocyte adhesion, antibiotics/antimicrobials, and other substances such as tachykinins, neurokinins or sialokinins, tachykinin NK receptor agonists; PDGF receptor inhibitors such as MLN-518 and derivatives thereof, butyric acid and butyric acid derivatives puerarin, fibronectin, erythropoietin, darbepotin, serine proteinase-1 (SERP-1) and the like. The aforementioned compounds and pharmaceutical substances can be applied to the coating on the device alone or in combinations and/or mixtures thereof.
  • In one embodiment, the implantable medical device can comprise a coating comprising one or more barrier layers in between said one or more layers of matrix comprising said pharmaceutical substances. In this embodiment, the barrier layer may comprise a suitable biodegradable material, including but not limited to suitable biodegradable polymers including: polyesters such as PLA, PGA, PLGA, PPF, PCL, PCC, TMC and any copolymer of these; polycarboxylic acid, polyanhydrides including maleic anhydride polymers; polyorthoesters; poly-amino acids; polyethylene oxide; polyphosphazenes; polylactic acid, polyglycolic acid and copolymers and mixtures thereof such as poly(L-lactic acid) (PLLA), poly(D,L-lactide), polylactic acid-co-glycolic acid), 50/50 (DL-lactide-co-glycolide); polydixanone; polypropylene fumarate; polydepsipeptides; polycaprolactone and co-polymers and mixtures thereof such as poly(D,L-lactide-co-caprolactone) and polycaprolactone co-butylacrylate; polyhydroxybutyrate valerate and blends; polycarbonates such as tyrosine-derived polycarbonates and arylates, polyiminocarbonates, and polydimethyltrimethyl-carbonates; cyanoacrylate; calcium phosphates; polyglycosaminoglycans; macromolecules such as polysaccharides (including hyaluronic acid; cellulose, and hydroxypropylmethyl cellulose; gelatin; starches; dextrans; alginates and derivatives thereof), proteins and polypeptides; and mixtures and copolymers of any of the foregoing. The biodegradable polymer may also be a surface erodable polymer such as polyhydroxybutyrate and its copolymers, polycaprolactone, polyanhydrides (both crystalline and amorphous), maleic anhydride copolymers, and zinc-calcium phosphate. The number of barrier layers that the coating on a device may have depends on the amount of therapeutic needed as dictated by the therapy required by the patient. For example, the longer the treatment, the more therapeutic substance required over a period of time, the more barrier layers to provide the pharmaceutical substance in a timely manner.
  • In one embodiment, the coating comprises a ligand which is applied to the blood contacting surface of the medical device and the ligand specifically recognizes and binds a desired component or epitope on the surface of target cells in the circulating blood. In one embodiment, the ligand is specifically designed to recognize and bind only the genetically-altered mammalian cell by recognizing only the genetically-engineered marker molecule on the cell membrane of the genetically-altered cells. The binding of the target cells immobilizes the cells on the surface of the device.
  • In alternate embodiment, the ligand on the surface of the medical device for binding the genetically-altered cell is selected depending on the genetically engineered cell membrane marker molecule. That is, the ligand binds only to the cell membrane marker molecule or antigen which is expressed by the cell from extrachromosomal genetic material provided to the cell so that only the genetically-modified cells can be recognized by the ligand on the surface of the medical device. In this manner, only the genetically-modified cells can bind to the surface of the medical device. For example, if the mammalian cell is an endothelial cell, the ligand can be at least one type of antibody, antibody fragments or combinations thereof; the antibody is specifically raised against a specific target epitope or marker molecule on the surface of the target cell. In this aspect of the invention, the antibody can be a monoclonal antibody, a polyclonal antibody, a chimeric antibody, or a humanized antibody which recognizes and binds only to the genetically-altered endothelial cell by interacting with the surface marker molecule and, thereby modulating the adherence of the cells onto the surface of the medical device. The antibody or antibody fragment of the invention can be covalently or noncovalently attached to the surface of the matrix, or tethered covalently by a linker molecule to the outermost layer of the matrix coating the medical device. In this embodiment, for example, the monoclonal antibodies can further comprises Fab or F(ab′)2 fragments. The antibody fragment of the invention comprises any fragment size, such as large and small molecules which retain the characteristic to recognize and bind the target antigen as the antibody.
  • In another embodiment, the antibody or antibody fragment of the invention recognize and bind antigens with specificity for the mammal being treated and their specificity is not dependent on cell lineage. In one embodiment, for example, in treating restenosis wherein the cells may not be genetically modified to contain specific cell membrane marker molecules, the antibody or fragment is specific for selecting and binding circulating progenitor endothelial cell surface antigen such as CD133, CD34, CD14, CDw90, CD117, HLA-DR, VEGFR-1, VEGFR-2, Muc-18 (CD146), CD130, stem cell antigen (Sea-1), stem cell factor 1 (SCF/c-Kit ligand), Tie-2, MHC such as H-2Kk and HLA-DR antigen.
  • In another embodiment, the coating of the medical device comprises at least one layer of a biocompatible matrix as described above, the matrix comprises an outer surface for attaching a therapeutically effective amount of at least one type of small molecule of natural or synthetic origin. The small molecule recognizes and interacts with, for example, progenitor endothelial cells in the treatment of restenosis, to immobilize the cells on the surface of the device to form an endothelial layer. The small molecules can be used in conjunction with the medical device for the treatment of various diseases, and can be derived from a variety of sources such as cellular components such as fatty acids, proteins, nucleic acids, saccharides and the like and can interact with an antigen on the surface of a progenitor endothelial cell with the same results or effects as an antibody. In this aspect of the invention, the coating on the medical device can further comprise a compound such as a growth factor as described herewith in conjunction with the coating comprising an antibody or antibody fragment.
  • In another embodiment, the coating of the medical device comprises at least one layer of a biocompatible matrix as described above, the matrix comprising a luminal surface for attaching a therapeutically effective amount of at least one type of small molecule of natural or synthetic origin. The small molecule recognizes and interacts with an antigen on the target cell such as a progenitor endothelial cell surface to immobilize the progenitor endothelial cell on the surface of the device to form endothelium. The small molecules can be derived from a variety of sources such as cellular components including, fatty acids, peptides, proteins, nucleic acids, saccharides and the like and can interact, for example, with a structure such as an antigen on the surface of a progenitor endothelial cell with the same results or effects as an antibody.
  • In another embodiment, there is provided a method for treating vascular disease such as restenosis and artherosclerosis, comprising administering a pharmaceutical substance locally to a patient in need of such substance. The method comprises implanting into a vessel or hollowed organ of a patient a medical device with a coating, which coating comprises a pharmaceutical composition comprising a drug or substance for inhibiting smooth muscle cell migration and thereby restenosis, and a biocompatible, biodegradable, bioerodible, nontoxic polymer or non-polymer matrix, wherein the pharmaceutical composition comprises a slow or controlled-release formulation for the delayed release of the drug. The coating on the medical device can also comprise a ligand such as an antibody for capturing cells such as endothelial cells and or progenitor cells on the luminal surface of the device so that a functional endothelium is formed.
  • In another embodiment, there is provided a method of making a coated medical device or a medical device with a coating, which comprises applying to a surface of a medical device a polymer or non-polymer matrix and a pharmaceutical composition comprising one or more drugs, and applying a ligand to the medical device so that the ligand attaches to a surface of the device and is designed to bind molecules on the cell membrane of circulating native or genetically engineered cells. In this embodiment, the polymer matrix comprises a biocompatible, biodegradable, nontoxic polymer matrix such as collagen, tropocollagen, elastin, tropoelastin, cross-linked tropoelastin, poly(lactide-co-glycolide) copolymer, polysaccharides and one or more pharmaceutical substances, wherein the matrix and the substance(s) can be mixed prior to applying to the medical device. In this embodiment, at least one type of ligand is applied to the surface of the device and can be added on top or on the outer surface of the device with the drug/matrix composition in contact with the device surface. The method may alternatively comprise the step of applying at least one layer of a pharmaceutical composition comprising one or more drugs and pharmaceutically acceptable carriers, and applying at least one layer of a polymer matrix to the medical device.
  • In one embodiment, the matrix can be applied as one or more layers and with or without the pharmaceutical substance, and the ligand can be applied independently to the medical device by several methods using standard techniques, such as dipping, spraying or vapor deposition. In an alternate embodiment, the polymer matrix can be applied to the device with or without the pharmaceutical substance. In this aspect of the invention wherein a polymer matrix is applied without the drug, the drug can be applied as a layer between layers of matrices. In other embodiments, a barrier layer is applied between the layers comprising the pharmaceutical substances.
  • In one embodiment, the method comprises applying the pharmaceutical composition as multiple layers with the ligand applied on the outermost surface of the medical device so that the ligand such as antibodies can be attached in the luminal surface of the device. In one embodiment, the method for coating the medical device comprises: applying to a surface of said medical device at least one or more layers of a matrix, one or more pharmaceutical substance(s), and a basement membrane component; applying to said at least one layer of said composition on said medical device a solution comprising at least one type of ligand for binding and immobilizing genetically-modified target cells; and drying said coating on the stent under vacuum at low temperatures.
  • In another embodiment, the coating is comprised of a multiple component pharmaceutical composition within the matrix such as containing a fast release pharmaceutical agent to retard early neointimal hyperplasia/smooth muscle cell migration and proliferation, and a secondary biostable matrix that releases a long acting agent for maintaining vessel patency or a positive blood vessel remodeling agent, such as endothelial nitric oxide synthase (eNOS), nitric oxide donors and derivatives such as aspirin or derivatives thereof, nitric oxide producing hydrogels, PPAR agonist such as PPAR-α ligands, tissue plasminogen activator, statins such as atorvastatin, erythropoietin, darbepotin, serine proteinase-1 (SERP-1) and pravastatin, steroids, and/or antibiotics.
  • The figures provided herewith depict embodiments that are described as illustrative examples that are not deemed in any way as limiting the present invention.
  • While the invention has been particularly shown and described with reference to particular embodiments, it will be appreciated that variations of the above-disclosed and other features and functions, or alternatives thereof, may be desirably combined into many other different systems or applications. Also that various presently unforeseen or unanticipated alternatives, modifications, variations or improvements therein may be subsequently made by those skilled in the art which are also intended to be encompassed by the following claims.

Claims (20)

  1. 1. A method for making a bioabsorbable polymeric implant comprising:
    (a) blending a composition comprising a base polymer of poly L-lactide or poly D-lactide linked with modifying copolymers comprising poly L(or D)-lactide-co-Tri-methylene-carbonate or poly L(or D)-lactide-co-ε-caprolactone in the form of block copolymers or as blocky random copolymers wherein the lactide chain length is sufficiently long enough to allow cross-moiety crystallization to form a polymer composition;
    (b) allowing said polymer composition to solidify to forming a desired mass; and
    (c) cutting said mass to form a configured implant.
  2. 2. The method of claim I wherein in step (a) the blending further entails blending a pharmacological and/or biological agent and/or radioopaque or radio-detectable material into the polymer composition.
  3. 3. A method in accord with claim I further comprising after step (a) the step of (a′) extruding said polymer composition.
  4. 4. A method in accord with claim 3 further comprising after or concurrent with step (a′), the step of: (a″) molding or casting said extruded polymer composition to form a molded polymer composition.
  5. 5. A method in accord with claim I wherein said desired mass, is selected from the group consisting of: a sheet, a tube, a rod, and a block,
  6. 6. A method in accord with claim 4 further comprising a step after step (b) of: (b″) spraying said solidified mass with a spray composition.
  7. 7. A method in accord with claim 6 wherein the spray composition of step (b″) comprises a biological or pharmacological agent.
  8. 8. A method in accord with claim 6 wherein, the spray composition comprises a radioopaque or radio-detectable material.
  9. 9. The method of claim 7 wherein the pharmacological agent(s) include at least one of the group consisting of: cyclosporin mycophenolic acid, mycophenolate mofetil acid, rapamycin, rapamycin derivatives, biolimus A9, CCI-779, RAD 001, AP23573, azathioprene, tacrolimus (FK506), tranilast, dexamethasone, corticosteroid, everolimus, pimecrolimus, retinoic acid, vitamin E, rosglitazone, simvastatins, fluvastatin, estrogen, 17-estradiol, hydrocortisone, acetaminophen, ibuprofen, naproxen, fluticasone, clobetasol, adalimumah, sulindac, dihydroepiandrosterone, testosterone, puerarin, platelet factor 4, basic fibroblast growth factor, fibronectin, butyric acid, butyric acid derivatives, paclitaxel, paclitaxel derivatives, LBM-642, deforolimus, and probucol.
  10. 10. The method of claim 7 wherein the biological agent(s) include at least one of the group consisting of: antibiotics/antimicrobials, antiproliferative agents, antineoplastic agents, antioxidants, endothelial cell growth factors, smooth muscle cell growth and/or migration inhibitors, thrombin inhibitors, immunosuppressive agents, anti-platelet aggregation agents, collagen synthesis inhibitors, therapeutic antibodies, nitric oxide donors, antisense oligonucleotides, wound healing agents, therapeutic gene transfer constructs, peptides, proteins, extracellular matrix components, vasodialators, thrombolytics, anti-metabolites, growth factor agonists, antimitotics, steroids, steroidal antiinflammatory agents, chemokines, proliferator-activated receptor-gamma agonists, proliferator-activated receptor-alpha agonists proliferator-activated receptor-beta agonists, proliferator-activated receptor-alpha/beta agonists, proliferator-activated receptor-delta agonists, N′FK, proliferator-activated receptor-alpha-gamma agonists, nonsterodial antiinflammatory agents, angiotensin converting enzyme(ACE) inhibitors, free radical scavangers, inhibitors of the CX3CR1 receptor and anti-cancer chemotherapeutic agents.
  11. 11. A method in accord with claim 4 further comprising a step after step (b) of: (b″) dipping said solidified mass into a composition having a pharmacological and/or biological agent.
  12. 12. A method for fabricating a medical device comprising:
    (a) preparing a biodegradable polymeric structure;
    (b) coating said biodegradable polymeric structure of step (a) with a polymeric coat including a pharmacological or biological agent;
    (c) after step (b) cutting said structure into patterns configured to allow for crimping of the cut structure and expansion of the cut structure after crimping into a deployed configuration.
  13. 13. A method in accord with claim 12 wherein said biodegradable polymeric structure prepared is in the form of a tube.
  14. 14. A method in accord with claim 12 wherein said polymeric coat is biodegradable.
  15. 15. A method in accord with claim 12 wherein said pharmacological agent of step (b) is at least one of the group consisting of: cyclosporin A, mycophenolic acid, mycophenolate mofetil acid, rapamycin, rapamycin derivatives, biolimus A9, CCI-779, RAD 001, AP23573, azathioprene, tacrolimus (FK506), tranilast, dexamethasone, corticosteroid, everolimus, retinoic acid, vitamin E, rosglitazone, simvastatins, fluvastatin, estrogen, 17P-estradiol, hydrocortisone, acetaminophen, ibuprofen, naproxen, fluticasone, clobetasol, adalimumab, sulindac, dihydroepiandrosterone, testosterone, puerarin, platelet factor 4, basic fibroblast growth factor, fibronectin, butyric acid, butyric acid derivatives, paclitaxel, paclitaxel derivatives, LBM-642 defbrolimus, and probucol
  16. 16. A method in accord with claim 12 wherein said biological agent of step (b) is at least one of the group consisting of: antibiotics/antimicrobials, antiproliferative agents, antineoplastic agents, antioxidants, endothelial cell growth factors, smooth muscle cell growth and/or migration inhibitors, thrombin inhibitors, immunosuppressive agents, anti-platelet aggregation agents, collagen synthesis inhibitors, therapeutic antibodies, nitric oxide donors, antisense oligonucleotides, wound healing agents, therapeutic gene transfer constructs, peptides, proteins, extracellular matrix components, vasodialators, thrombolytics, anti-metabolites, growth factor agonists, antimitotics, steroids, steroidal antiinflammatory agents, chemokines, proliferator-activated receptor-gamma agonists, proliferator-activated receptor-alpha agonists proliferator-activated receptor-beta agonists, proliferator-activated receptor-alpha/beta agonists, proliferator-activated receptor-delta agonists, NFKP, proliferator-activated receptor-alpha-gamma agonists, nonsterodial antiinflammatory agents, angiotensin converting enzyme(ACE) inhibitors, free radical scavangers, inhibitors of the CX3CR1 receptor and anti-cancer chemotherapeutic agents.
  17. 17. A method for fabricating a medical device comprising:
    (a) blending a composition comprising a base polymer of poly L-lactide or poly D-lactide linked with modifying copolymers comprising poly L(or D)-lactide-co-Tri-methylene-carbonate or poly L(or D)-lactide-co-s-caprolactone in the form of block copolymers or as blocky random copolymers wherein the lactide chain length is sufficiently long enough to allow cross-moiety crystallization to form a polymer composition;
    (b) extruding said polymer composition through an extrusion device;
    (c) coating said extruded polymer composition of step (b) with a coating comprising a pharmacological or biological agent;
    (d) cutting said coated polymer composition of step (c) to form configured patterns in said polymer composition, said patterns configured to allow for crimping of the cut structure and expansion of the cut structure after crimping into a deployed configuration.
  18. 18. A method in accord with claim 17 further comprising after step (c) the step of: (c′) extruding the same or another polymer composition onto the extruded polymer composition of step (b) as coated in step (c), such co-extruded polymer composition comprising a pharmacological or biological agent.
  19. 19. A method in accord with claim 10 wherein step (c′) is repeated multiple times to produces a multi-layer extrusion.
  20. 20. (canceled)
US15671050 2006-10-20 2017-08-07 Bioabsorbable polymeric composition and medical device Pending US20180056569A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US86243306 true 2006-10-20 2006-10-20
US11875892 US8691321B2 (en) 2006-10-20 2007-10-20 Bioabsorbable polymeric composition and medical device background
US14197357 US9724864B2 (en) 2006-10-20 2014-03-05 Bioabsorbable polymeric composition and medical device
US15671050 US20180056569A1 (en) 2006-10-20 2017-08-07 Bioabsorbable polymeric composition and medical device

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15671050 US20180056569A1 (en) 2006-10-20 2017-08-07 Bioabsorbable polymeric composition and medical device

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14197357 Continuation US9724864B2 (en) 2006-10-20 2014-03-05 Bioabsorbable polymeric composition and medical device

Publications (1)

Publication Number Publication Date
US20180056569A1 true true US20180056569A1 (en) 2018-03-01

Family

ID=39492919

Family Applications (3)

Application Number Title Priority Date Filing Date
US11875892 Active 2028-01-28 US8691321B2 (en) 2006-10-20 2007-10-20 Bioabsorbable polymeric composition and medical device background
US14197357 Active US9724864B2 (en) 2006-10-20 2014-03-05 Bioabsorbable polymeric composition and medical device
US15671050 Pending US20180056569A1 (en) 2006-10-20 2017-08-07 Bioabsorbable polymeric composition and medical device

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11875892 Active 2028-01-28 US8691321B2 (en) 2006-10-20 2007-10-20 Bioabsorbable polymeric composition and medical device background
US14197357 Active US9724864B2 (en) 2006-10-20 2014-03-05 Bioabsorbable polymeric composition and medical device

Country Status (4)

Country Link
US (3) US8691321B2 (en)
EP (1) EP2073754A4 (en)
CN (2) CN101631513B (en)
WO (1) WO2008070304A3 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
ES2283398T3 (en) * 2000-03-15 2007-11-01 Orbusneich Medical, Inc. Coating improves the adhesion of endothelial cells.
US7846361B2 (en) * 2006-07-20 2010-12-07 Orbusneich Medical, Inc. Bioabsorbable polymeric composition for a medical device
CN103494661B (en) * 2006-07-20 2016-03-30 奥巴斯尼茨医学公司 Bioabsorbable polymeric medical
US8460362B2 (en) * 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
US20110130822A1 (en) * 2007-07-20 2011-06-02 Orbusneich Medical, Inc. Bioabsorbable Polymeric Compositions and Medical Devices
US7959942B2 (en) * 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
US8414638B2 (en) * 2008-03-12 2013-04-09 Abbott Cardiovascular Systems Inc. Method for fabricating a polymer stent with break-away links for enhanced stent retenton
US20100057187A1 (en) * 2008-08-26 2010-03-04 Caldarise Salvatore G Intravascular stent having imrproved design for loading and deploying
WO2010042854A1 (en) * 2008-10-10 2010-04-15 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
US20100093946A1 (en) * 2008-10-11 2010-04-15 Orbusneich Medical, Inc. Bioabsorbable Polymeric Compositions and Medical Devices
GB2472603B (en) * 2009-08-11 2011-12-14 Cook Medical Technologies Llc Implantable medical device
US8226705B2 (en) * 2009-09-18 2012-07-24 Medtronic Vascular, Inc. Methods for forming an orthogonal end on a helical stent
US9345602B2 (en) 2010-09-23 2016-05-24 Abbott Cardiovascular Systems Inc. Processes for making crush recoverable polymer scaffolds
US8808353B2 (en) 2010-01-30 2014-08-19 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds having a low crossing profile
US8568471B2 (en) 2010-01-30 2013-10-29 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds
JP5914479B2 (en) * 2010-08-02 2016-05-11 コーディス・コーポレイションCordis Corporation Flexible helical stent having a non-helical intermediate region
US10098765B2 (en) 2010-12-15 2018-10-16 Biotronik Ag Implant and method for producing the same
US20140275904A1 (en) * 2013-03-14 2014-09-18 Cell and Molecular Tissue Engineering, LLC Sensors, Sensor Systems and Methods
US9717583B2 (en) * 2014-03-13 2017-08-01 Cell and Molecular Tissue Engineering, LLC Sensors, cannulas, collars and coated surgical mesh, and corresponding systems and methods
CN106361478B (en) * 2016-11-02 2018-08-21 江苏大学 Hybrid seed balloon-expandable vascular stent

Family Cites Families (302)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057537A (en) 1975-01-28 1977-11-08 Gulf Oil Corporation Copolymers of L-(-)-lactide and epsilon caprolactone
US4300565A (en) 1977-05-23 1981-11-17 American Cyanamid Company Synthetic polyester surgical articles
US4243775A (en) 1978-11-13 1981-01-06 American Cyanamid Company Synthetic polyester surgical articles
US4379138A (en) 1981-12-28 1983-04-05 Research Triangle Institute Biodegradable polymers of lactones
US4655777A (en) 1983-12-19 1987-04-07 Southern Research Institute Method of producing biodegradable prosthesis and products therefrom
US4650488A (en) 1984-05-16 1987-03-17 Richards Medical Company Biodegradable prosthetic device
US4944974A (en) 1984-10-24 1990-07-31 Zachariades Anagnostis E Composite structures of ultra-high-molecular-weight polymers, such as ultra-high-molecular-weight polyethylene products, and method of producing such structures
US4719246A (en) 1986-12-22 1988-01-12 E. I. Du Pont De Nemours And Company Polylactide compositions
FI81498C (en) 1987-01-13 1990-11-12 Biocon Oy Kirurgiska goods and the instrument.
DE3708916C2 (en) 1987-03-19 1989-10-12 Boehringer Ingelheim Kg, 6507 Ingelheim, De
US5145945A (en) 1987-12-17 1992-09-08 Allied-Signal Inc. Homopolymers and copolymers having recurring carbonate units
US5185408A (en) 1987-12-17 1993-02-09 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US4916193A (en) 1987-12-17 1990-04-10 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5066772A (en) * 1987-12-17 1991-11-19 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5274074A (en) 1987-12-17 1993-12-28 United States Surgical Corporation Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US5120802A (en) * 1987-12-17 1992-06-09 Allied-Signal Inc. Polycarbonate-based block copolymers and devices
US5256764A (en) 1987-12-17 1993-10-26 United States Surgical Corporation Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US6740731B2 (en) 1988-08-08 2004-05-25 Cargill Dow Polymers Llc Degradation control of environmentally degradable disposable materials
US5502158A (en) 1988-08-08 1996-03-26 Ecopol, Llc Degradable polymer composition
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5085629A (en) * 1988-10-06 1992-02-04 Medical Engineering Corporation Biodegradable stent
FI85223C (en) 1988-11-10 1992-03-25 Biocon Oy Biodegraderande kirurgiska implant and means.
US6171338B1 (en) 1988-11-10 2001-01-09 Biocon, Oy Biodegradable surgical implants and devices
US5290494A (en) 1990-03-05 1994-03-01 Board Of Regents, The University Of Texas System Process of making a resorbable implantation device
NL9000959A (en) 1990-04-21 1991-11-18 Stamicarbon A catalyst for the polymerization of cyclic esters.
US5097005A (en) 1990-05-11 1992-03-17 E. I. Du Pont De Nemours And Company Novel copolyesters and their use in compostable products such as disposable diapers
US5342395A (en) 1990-07-06 1994-08-30 American Cyanamid Co. Absorbable surgical repair devices
NL9001641A (en) 1990-07-19 1992-02-17 Stamicarbon A process for making polymeric products of cyclic esters.
NL9001984A (en) 1990-09-10 1992-04-01 Stamicarbon A method for producing an article from a copolymer of lactide and epsilon-caprolactone for medical applications.
US5320624A (en) 1991-02-12 1994-06-14 United States Surgical Corporation Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorbable surgical devices made therefrom
US5250373A (en) * 1991-09-10 1993-10-05 Wilson Greatbatch Ltd. Internal electrode and assembly method for electrochemical cells
US5500013A (en) 1991-10-04 1996-03-19 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5302397A (en) 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
NL9102148A (en) 1991-12-20 1993-07-16 Dsm Nv Copolymer of lactone and carbonate, and the process for obtaining it.
US5225521A (en) 1991-12-31 1993-07-06 E. I. Du Pont De Nemours And Company Star-shaped hydroxyacid polymers
US5142023A (en) 1992-01-24 1992-08-25 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5338822A (en) 1992-10-02 1994-08-16 Cargill, Incorporated Melt-stable lactide polymer composition and process for manufacture thereof
US5322925A (en) 1992-10-30 1994-06-21 United States Surgical Corporation Absorbable block copolymers and surgical articles made therefrom
NL9201949A (en) 1992-11-06 1994-06-01 Univ Groningen The rubber-modified polylactide composition.
DE4239781A1 (en) 1992-11-26 1994-06-01 Basf Ag Moldings of foamed polylactides and processes for their preparation
US5317064A (en) * 1992-12-11 1994-05-31 E. I. Du Pont De Nemours And Company Manufacture of polylactide stereocomplexes
US6221958B1 (en) 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
GB2281865B (en) 1993-09-16 1997-07-30 Cordis Corp Endoprosthesis having multiple laser welded junctions,method and procedure
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
NL9400519A (en) 1994-03-31 1995-11-01 Rijksuniversiteit Intravascular polymeric stent.
US20020032488A1 (en) 1994-05-13 2002-03-14 Brekke John H. Device for regeneration of articular cartilage and other tissue
DE59508729D1 (en) 1994-08-10 2000-10-26 Peter Neuenschwander biocompatible block copolymer
JP3379841B2 (en) 1994-10-28 2003-02-24 高砂香料工業株式会社 Block copolymers of poly (ester - carbonates), and a manufacturing method thereof
US7001328B1 (en) 1994-11-15 2006-02-21 Kenton W. Gregory Method for using tropoelastin and for producing tropoelastin biomaterials
WO1996019519A1 (en) 1994-12-21 1996-06-27 Universiteit Twente Catalytic ring opening polymerization of lactones, carbonates, ethers, morpholine-2,5-diones and anhydrides and catalyst therefor
US7204848B1 (en) 1995-03-01 2007-04-17 Boston Scientific Scimed, Inc. Longitudinally flexible expandable stent
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5691424A (en) 1995-05-25 1997-11-25 Mitsui Toatsu Chemicals, Inc. Heat-resistant molded article of lactic acid-base polymer
GB9514285D0 (en) * 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
US6107453A (en) 1995-07-28 2000-08-22 Sanitaria Scaligera S.P.A. Process of surface activation of biocompatible and bioabsorbable aliphatic polyesters and polyesters thus activated
DE69636626D1 (en) 1995-07-28 2006-11-23 Genzyme Corp Biodegradable multiblokhydrogene and werstoffe activen pharmacologically their use as carrier materials for controlled release and tissue contact materials
FI954565A0 (en) 1995-09-27 1995-09-27 Biocon Oy Biolgiskt upploeslig of a material polymerbaserat Tillverkad implant och dess foerfarande Foer Tillverkning
FI98136C (en) 1995-09-27 1997-04-25 Biocon Oy Tissue conditions degradable material and a method for its preparation
US5849374A (en) 1995-09-28 1998-12-15 Cargill, Incorporated Compostable multilayer structures, methods for manufacture, and articles prepared therefrom
US5849401A (en) 1995-09-28 1998-12-15 Cargill, Incorporated Compostable multilayer structures, methods for manufacture, and articles prepared therefrom
US20010051833A1 (en) 1995-10-11 2001-12-13 Walter Mary Ann Moldable, hand-shapable biodegradable implant material
US5776161A (en) * 1995-10-16 1998-07-07 Instent, Inc. Medical stents, apparatus and method for making same
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
DE19545257A1 (en) 1995-11-24 1997-06-19 Schering Ag A process for the production of morphologically uniform microcapsules and produced by this process microcapsules
US5670161A (en) 1996-05-28 1997-09-23 Healy; Kevin E. Biodegradable stent
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5916950A (en) 1996-07-26 1999-06-29 Mitsui Chemicals, Inc. Resin composition and molded articles thereof
US5925061A (en) 1997-01-13 1999-07-20 Gore Enterprise Holdings, Inc. Low profile vascular stent
WO1998044020A1 (en) 1997-04-03 1998-10-08 Guilford Pharmaceuticals Inc. Biodegradable polymers chain-extended by phosphates, compositions, articles and methods for making and using the same
US10028851B2 (en) 1997-04-15 2018-07-24 Advanced Cardiovascular Systems, Inc. Coatings for controlling erosion of a substrate of an implantable medical device
US6033433A (en) 1997-04-25 2000-03-07 Scimed Life Systems, Inc. Stent configurations including spirals
EP0884029B1 (en) 1997-06-13 2004-12-22 Gary J. Becker Expandable intraluminal endoprosthesis
FI972890A (en) 1997-07-08 1999-01-09 Bioxid Oy The new plastic-based composite and its käytt|
US6245103B1 (en) 1997-08-01 2001-06-12 Schneider (Usa) Inc Bioabsorbable self-expanding stent
GB9717433D0 (en) 1997-08-19 1997-10-22 Univ Nottingham Biodegradable composites
US6297349B1 (en) 1998-08-25 2001-10-02 Union Carbide Chemicals & Plastics Technology Corporation Condensation copolymers having supressed crystallinity
US5948016A (en) 1997-09-25 1999-09-07 Jang; G. David Intravascular stent with non-parallel slots
US6165217A (en) 1997-10-02 2000-12-26 Gore Enterprise Holdings, Inc. Self-cohering, continuous filament non-woven webs
US6110164A (en) * 1997-12-05 2000-08-29 Intratherapeutics, Inc. Guideless catheter segment
US6033394A (en) * 1997-12-05 2000-03-07 Intratherapeutics, Inc. Catheter support structure
US5964798A (en) * 1997-12-16 1999-10-12 Cardiovasc, Inc. Stent having high radial strength
US6921811B2 (en) 1998-09-22 2005-07-26 Biosurface Engineering Technologies, Inc. Bioactive coating composition and methods
JP2002500065A (en) 1998-01-06 2002-01-08 バイオアミド・インコーポレイテッド Bioabsorbable fiber and reinforced composites produced therefrom
US20020011167A1 (en) * 1998-01-15 2002-01-31 Murray Figov Plateless printing system
US7070607B2 (en) * 1998-01-27 2006-07-04 The Regents Of The University Of California Bioabsorbable polymeric implants and a method of using the same to create occlusions
US6623521B2 (en) 1998-02-17 2003-09-23 Md3, Inc. Expandable stent with sliding and locking radial elements
US6558415B2 (en) 1998-03-27 2003-05-06 Intratherapeutics, Inc. Stent
DE69935716T2 (en) * 1998-05-05 2007-08-16 Boston Scientific Ltd., St. Michael Stent with smooth end
JP4342734B2 (en) * 1998-10-29 2009-10-14 寛治 井上 Guidance system of the instrument
US6255408B1 (en) 1998-11-06 2001-07-03 Poly-Med, Inc. Copolyesters with minimized hydrolytic instability and crystalline absorbable copolymers thereof
US6350464B1 (en) 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
US6365173B1 (en) 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
JP4548623B2 (en) * 1999-02-24 2010-09-22 多木化学株式会社 Biological material
US6251134B1 (en) * 1999-02-28 2001-06-26 Inflow Dynamics Inc. Stent with high longitudinal flexibility
US6206883B1 (en) 1999-03-05 2001-03-27 Stryker Technologies Corporation Bioabsorbable materials and medical devices made therefrom
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US6730116B1 (en) * 1999-04-16 2004-05-04 Medtronic, Inc. Medical device for intraluminal endovascular stenting
US6273911B1 (en) * 1999-04-22 2001-08-14 Advanced Cardiovascular Systems, Inc. Variable strength stent
US6368346B1 (en) 1999-06-03 2002-04-09 American Medical Systems, Inc. Bioresorbable stent
FR2795438B1 (en) 1999-06-28 2001-08-03 Dumez Gtm Structural bridge or mixed concrete-steel bridge, in particular a mixed double girder bridge deck under floor
US6306424B1 (en) 1999-06-30 2001-10-23 Ethicon, Inc. Foam composite for the repair or regeneration of tissue
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
US6333029B1 (en) 1999-06-30 2001-12-25 Ethicon, Inc. Porous tissue scaffoldings for the repair of regeneration of tissue
US6709427B1 (en) 1999-08-05 2004-03-23 Kensey Nash Corporation Systems and methods for delivering agents into targeted tissue of a living being
US6352667B1 (en) 1999-08-24 2002-03-05 Absorbable Polymer Technologies, Inc. Method of making biodegradable polymeric implants
US20030144570A1 (en) 1999-11-12 2003-07-31 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
WO2001042333A3 (en) 1999-12-13 2001-12-06 Univ Michigan State Process for the preparation of polymers of dimeric cyclic esters
US6338739B1 (en) * 1999-12-22 2002-01-15 Ethicon, Inc. Biodegradable stent
US6740100B2 (en) 1999-12-23 2004-05-25 Omeros Corporation Tendon repair using adhesive
US6312458B1 (en) 2000-01-19 2001-11-06 Scimed Life Systems, Inc. Tubular structure/stent/stent securement member
US6575888B2 (en) * 2000-01-25 2003-06-10 Biosurface Engineering Technologies, Inc. Bioabsorbable brachytherapy device
US7592017B2 (en) 2000-03-10 2009-09-22 Mast Biosurgery Ag Resorbable thin membranes
US20060083767A1 (en) 2003-02-27 2006-04-20 Kai Deusch Surgical prosthesis having biodegradable and nonbiodegradable regions
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20160287708A9 (en) 2000-03-15 2016-10-06 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20050271701A1 (en) 2000-03-15 2005-12-08 Orbus Medical Technologies, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US20070141107A1 (en) 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
GB0011356D0 (en) 2000-05-12 2000-06-28 Univ Nottingham Trent Medical implant materials
US6652579B1 (en) 2000-06-22 2003-11-25 Advanced Cardiovascular Systems, Inc. Radiopaque stent
EP1301197A2 (en) 2000-07-21 2003-04-16 Board Of Regents The University Of Texas System Device providing regulated growth factor delivery for the regeneration of peripheral nerves
CA2420348C (en) 2000-08-24 2009-08-04 Cornell Research Foundation, Inc. Non-hormonal vaginal contraceptive
US6254632B1 (en) * 2000-09-28 2001-07-03 Advanced Cardiovascular Systems, Inc. Implantable medical device having protruding surface structures for drug delivery and cover attachment
WO2002031037A1 (en) 2000-10-11 2002-04-18 Union Carbide Chemicals & Plastics Technology Corporation Compositions comprising crystalline condensation polymers and nucleating agents
US20060142765A9 (en) 2001-10-15 2006-06-29 Dixon Robert A Vertebral implant for bone fixation or interbody use
EP1208754A1 (en) 2000-11-21 2002-05-29 Givaudan SA Particulate material
US20020106406A1 (en) 2000-12-08 2002-08-08 Mchugh Anthony J. Crystallizable/non-crystallizable polymer composites
US20030049320A1 (en) 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
JP2004516262A (en) 2000-12-21 2004-06-03 ネクター セラピューティクス Induced phase transition method for the preparation of microparticles containing an hydrophilic active
DE10064108A1 (en) * 2000-12-21 2002-07-18 Siemens Production & Logistics Placement and placement system for a placement device for placing components
US20040220660A1 (en) 2001-02-05 2004-11-04 Shanley John F. Bioresorbable stent with beneficial agent reservoirs
US6540777B2 (en) 2001-02-15 2003-04-01 Scimed Life Systems, Inc. Locking stent
US6949251B2 (en) 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
DE10113302B4 (en) 2001-03-19 2009-09-24 Fraunhofer-Gesellschaft für die angewandte Forschung e.V. A process for the preparation of homo- and copolyesters of the lactic acid
US6656488B2 (en) 2001-04-11 2003-12-02 Ethicon Endo-Surgery, Inc. Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering
US6607548B2 (en) 2001-05-17 2003-08-19 Inion Ltd. Resorbable polymer compositions
CN1169494C (en) * 2001-05-23 2004-10-06 中国科学院化学研究所 Cell scaffold with composite structure for tissue engineering and its preparing process and application
US6599314B2 (en) 2001-06-08 2003-07-29 Cordis Corporation Apparatus and method for stenting a vessel using balloon-actuated stent with interlocking elements
US6645618B2 (en) 2001-06-15 2003-11-11 3M Innovative Properties Company Aliphatic polyester microfibers, microfibrillated articles and use thereof
US6890649B2 (en) 2002-04-26 2005-05-10 3M Innovative Properties Company Aliphatic polyester microfibers, microfibrillated articles and use thereof
US6730772B2 (en) 2001-06-22 2004-05-04 Venkatram P. Shastri Degradable polymers from derivatized ring-opened epoxides
KR100448170B1 (en) 2001-06-23 2004-09-10 주식회사 태평양 Amphiphilic biodegradable block copolymers comprising polyethylenimine(PEI) as a hydrophilic block and polyester as a hydrophobic block, and self-assembled polymer aggregates in aqueous milieu formed from the block copolymers
US6585755B2 (en) * 2001-06-29 2003-07-01 Advanced Cardiovascular Polymeric stent suitable for imaging by MRI and fluoroscopy
KR100383433B1 (en) 2001-06-29 2003-05-12 주식회사 씨엠리서치 Method for preparing bioabsorbable organic/inorganic composition for bone fixation devices and itself prepared thereby
US20030050687A1 (en) 2001-07-03 2003-03-13 Schwade Nathan D. Biocompatible stents and method of deployment
US20070100358A2 (en) 2002-08-01 2007-05-03 Texas Scottish Rite Hospital For Children A Biomimetic Synthetic Nerve Implant
US20060004437A1 (en) 2001-08-29 2006-01-05 Swaminathan Jayaraman Structurally variable stents
US20060188486A1 (en) * 2003-10-14 2006-08-24 Medivas, Llc Wound care polymer compositions and methods for use thereof
US6747121B2 (en) 2001-09-05 2004-06-08 Synthes (Usa) Poly(L-lactide-co-glycolide) copolymers, methods for making and using same, and devices containing same
US20050025808A1 (en) 2001-09-24 2005-02-03 Herrmann Robert A. Medical devices and methods for inhibiting smooth muscle cell proliferation
GB0124742D0 (en) 2001-10-16 2001-12-05 Biocomposites Ltd Biodegradable materials
US8105652B2 (en) 2002-10-24 2012-01-31 Massachusetts Institute Of Technology Methods of making decomposable thin films of polyelectrolytes and uses thereof
US7572287B2 (en) 2001-10-25 2009-08-11 Boston Scientific Scimed, Inc. Balloon expandable polymer stent with reduced elastic recoil
US20030082148A1 (en) 2001-10-31 2003-05-01 Florian Ludwig Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7595043B2 (en) 2001-12-07 2009-09-29 Cytori Therapeutics, Inc. Method for processing and using adipose-derived stem cells
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
US20060177495A1 (en) 2001-12-21 2006-08-10 Christine Allen Polymer-lipid delivery vehicles
US6866805B2 (en) * 2001-12-27 2005-03-15 Advanced Cardiovascular Systems, Inc. Hybrid intravascular stent
US20030212449A1 (en) 2001-12-28 2003-11-13 Cox Daniel L. Hybrid stent
US20050001358A1 (en) 2001-12-28 2005-01-06 Kenji Nakazawa Polylactic acid-based resin compositions, molded articles and process for producing the same
US7326245B2 (en) 2002-01-31 2008-02-05 Boston Scientific Scimed, Inc. Medical device for delivering biologically active material
EP1334990A1 (en) 2002-02-06 2003-08-13 Polyganics B.V. DL-Lactide-epsilon-caprolactone copolymers
US6887270B2 (en) 2002-02-08 2005-05-03 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US20060093771A1 (en) 2002-02-15 2006-05-04 Frantisek Rypacek Polymer coating for medical devices
DE10206924B4 (en) 2002-02-19 2005-12-15 Papierfabrik Schoeller & Hoesch Gmbh & Co. Kg Heat sealable filter materials
JP2003253009A (en) 2002-03-06 2003-09-10 Unitika Ltd Polylactic acid based molded product and production method therefor
JP2005529095A (en) 2002-04-10 2005-09-29 ネモサイエンス、ゲーエムベーハーMnemoscience Gmbh How to achieve the shape memory effect in hair
US20030211135A1 (en) 2002-04-11 2003-11-13 Greenhalgh Skott E. Stent having electrospun covering and method
US20030195611A1 (en) 2002-04-11 2003-10-16 Greenhalgh Skott E. Covering and method using electrospinning of very small fibers
GB0208418D0 (en) 2002-04-11 2002-05-22 Univ Aston Polymeric fibre
US20050187605A1 (en) 2002-04-11 2005-08-25 Greenhalgh Skott E. Electrospun skin capable of controlling drug release rates and method
DE10216834A1 (en) 2002-04-16 2003-11-13 Fraunhofer Ges Forschung A process for preparing melt stable homo- and copolyesters of cyclic esters and / or diesters
DE10217350C1 (en) 2002-04-18 2003-12-18 Mnemoscience Gmbh polyesterurethanes
DE10217351B3 (en) 2002-04-18 2004-02-12 Mnemoscience Gmbh interpenetrating networks
US6869985B2 (en) 2002-05-10 2005-03-22 Awi Licensing Company Environmentally friendly polylactide-based composite formulations
US7354656B2 (en) 2002-11-26 2008-04-08 Michigan State University, Board Of Trustees Floor covering made from an environmentally friendly polylactide-based composite formulation
US7166133B2 (en) 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US6794484B2 (en) 2002-06-28 2004-09-21 Ethicon, Inc. Crystallizable polylactone copolymers prepared from mono- and di-functional polymerization initiators
US6831149B2 (en) 2002-06-28 2004-12-14 Ethicon, Inc. Polymerization process using mono-and di-functional initiators to prepare fast crystallizing polylactone copolymers
US20040006146A1 (en) 2002-07-06 2004-01-08 Evans Douglas G. Resorbable structure for treating and healing of tissue defects
US7160551B2 (en) 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
EP1382628A1 (en) 2002-07-16 2004-01-21 Polyganics B.V. Biodegradable phase separated segmented/block co-polyesters
US7824699B2 (en) 2002-07-22 2010-11-02 Biodynamics Llc Implantable prosthetic devices containing timed release therapeutic agents
US6916483B2 (en) 2002-07-22 2005-07-12 Biodynamics, Llc Bioabsorbable plugs containing drugs
EP1528901A1 (en) * 2002-08-15 2005-05-11 GMP Cardiac Care, Inc. Stent-graft with rails
EP1549154A1 (en) 2002-09-24 2005-07-06 Gumlink A/S Degradable chewing gum polymer
CA2497349C (en) 2002-09-26 2008-07-08 Angiotech International Ag Perivascular wraps
US6770729B2 (en) * 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
WO2004033539A1 (en) * 2002-10-11 2004-04-22 University Of Connecticut Blends of amorphous and semicrystalline polymers having shape memory properties
US20040098090A1 (en) * 2002-11-14 2004-05-20 Williams Michael S. Polymeric endoprosthesis and method of manufacture
US7291345B2 (en) 2002-12-12 2007-11-06 Osteotech, Inc. Formable and settable polymer bone composite and method of production thereof
US6896697B1 (en) * 2002-12-30 2005-05-24 Advanced Cardiovascular Systems, Inc. Intravascular stent
JP2004224990A (en) 2003-01-27 2004-08-12 Suzuki Motor Corp Polylactic acid-based polymer resin composition and molding of the same
US7435789B2 (en) 2003-01-31 2008-10-14 Poly-Med, Inc. Crystalline high-compliance glycolide copolymers and applications thereof
DK1589826T3 (en) 2003-02-04 2009-08-03 Gumlink As Compressed chewing gum tablet
CN1446833A (en) 2003-02-08 2003-10-08 复旦大学 Warm sensitivity degradable micro gelatin and its preparation method
US20060233887A1 (en) 2003-02-14 2006-10-19 The North West London Hospitals N H S Trust Bioactive material for use in stimulating vascularization
US20040167572A1 (en) * 2003-02-20 2004-08-26 Roth Noah M. Coated medical devices
US7918884B2 (en) 2003-02-25 2011-04-05 Cordis Corporation Stent for treatment of bifurcated lesions
US20080051866A1 (en) 2003-02-26 2008-02-28 Chao Chin Chen Drug delivery devices and methods
US7169118B2 (en) 2003-02-26 2007-01-30 Scimed Life Systems, Inc. Elongate medical device with distal cap
US20040249442A1 (en) 2003-02-26 2004-12-09 Fleming James A. Locking stent having multiple locking points
US6932930B2 (en) 2003-03-10 2005-08-23 Synecor, Llc Intraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same
US8221781B2 (en) 2003-04-11 2012-07-17 Etex Corporation Osteoinductive bone material
US7972616B2 (en) 2003-04-17 2011-07-05 Nanosys, Inc. Medical device applications of nanostructured surfaces
CN1320044C (en) 2003-04-25 2007-06-06 株式会社艾迪科 Polylactic acids compsns. make-up products and preparation process thereof
EP1653865A2 (en) 2003-05-23 2006-05-10 Angiotech International Ag Anastomotic connector devices
WO2004108180A1 (en) 2003-06-04 2004-12-16 Inion Ltd Biodegradable implant and method for manufacturing one
WO2004110315A1 (en) 2003-06-16 2004-12-23 Nanyang Technological University Polymeric stent and method of manufacture
CN1835723B (en) 2003-06-16 2011-06-22 洛马林达大学医学中心 Deployable multifunctional hemostatic agent
WO2005041811A3 (en) 2003-06-16 2006-04-13 James Drake Deployable hemostatic agent
US6974862B2 (en) 2003-06-20 2005-12-13 Kensey Nash Corporation High density fibrous polymers suitable for implant
US20080267901A1 (en) 2003-07-03 2008-10-30 Dirk Wybe Grijpma Biocompatible Polymer Networks
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
ES2537307T3 (en) 2003-07-16 2015-06-05 Eidgenössische Technische Hochschule Zürich Biocompatible block copolymer, degradable
DE10334823A1 (en) 2003-07-30 2005-02-24 Mnemoscience Gmbh Method of treating hair with shape memory polymers
DE10334784A1 (en) 2003-07-30 2005-03-03 Mnemoscience Gmbh Cosmetic composition with polyol / polyester block polymers
US8529625B2 (en) 2003-08-22 2013-09-10 Smith & Nephew, Inc. Tissue repair and replacement
US7494950B2 (en) 2003-09-05 2009-02-24 Synthes (U.S.A.) Bone cement compositions having fiber-reinforcement and/or increased flowability
US20050249697A1 (en) 2003-09-24 2005-11-10 Uhrich Kathryn E Compositions and methods for the inhibition of bone growth and resorption
US20050202067A1 (en) 2003-10-28 2005-09-15 Gkss Forschungszentrum Matrix structure and hybrid matrix system for inducing a neofacia, their use and method for generating a neofacia
US20050208095A1 (en) 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
WO2005065079A3 (en) 2003-11-10 2007-01-25 Angiotech Int Ag Medical implants and fibrosis-inducing agents
US7264641B2 (en) 2003-11-10 2007-09-04 Cabot Microelectronics Corporation Polishing pad comprising biodegradable polymer
WO2005049105A8 (en) 2003-11-10 2005-10-13 Angiotech Int Ag Medical implants and anti-scarring agents
US8192752B2 (en) 2003-11-21 2012-06-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same
US7807722B2 (en) 2003-11-26 2010-10-05 Advanced Cardiovascular Systems, Inc. Biobeneficial coating compositions and methods of making and using thereof
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20050209603A1 (en) 2003-12-02 2005-09-22 St. Francis Medical Technologies, Inc. Method for remediation of intervertebral disks
WO2005059003A1 (en) 2003-12-15 2005-06-30 The Children's Hospital Of Philadelphia Novel polyesters
GB0329654D0 (en) 2003-12-23 2004-01-28 Smith & Nephew Tunable segmented polyacetal
CN101897989B (en) 2004-02-23 2013-11-13 洛马林达大学医学中心 Hemostatic agent for topical and internal use
US7691381B2 (en) 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US7723395B2 (en) 2004-04-29 2010-05-25 Kensey Nash Corporation Compressed porous materials suitable for implant
US7820732B2 (en) 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US20050281856A1 (en) 2004-05-10 2005-12-22 Mcglohorn Jonathan Implantable biostructure comprising an osteoconductive member and an osteoinductive material
CA2564605A1 (en) 2004-05-12 2005-12-01 Massachusetts Institute Of Technology Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like
US20060018942A1 (en) 2004-05-28 2006-01-26 Rowe Charles W Polymeric microbeads having characteristics favorable for bone growth, and process including three dimensional printing upon such microbeads
US8012501B2 (en) 2004-06-10 2011-09-06 Synthes Usa, Llc Flexible bone composite
US7754874B2 (en) 2004-06-24 2010-07-13 Wisconsin Alumni Research Foundation Neoglycorandomization and digitoxin analogs
EP1781305A2 (en) 2004-08-13 2007-05-09 Angiotech International Ag Compositions and methods using hyaluronic acid and hyaluronidase inhibitors
US20060041102A1 (en) 2004-08-23 2006-02-23 Advanced Cardiovascular Systems, Inc. Implantable devices comprising biologically absorbable polymers having constant rate of degradation and methods for fabricating the same
US7919112B2 (en) 2004-08-26 2011-04-05 Pathak Holdings, Llc Implantable tissue compositions and method
US7244443B2 (en) 2004-08-31 2007-07-17 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrophilic monomers
US9011831B2 (en) 2004-09-30 2015-04-21 Advanced Cardiovascular Systems, Inc. Methacrylate copolymers for medical devices
US7166680B2 (en) 2004-10-06 2007-01-23 Advanced Cardiovascular Systems, Inc. Blends of poly(ester amide) polymers
CN101137347A (en) 2004-11-16 2008-03-05 列日大学 Active substance delivery system comprising a hydrogel atrix and microcarriers
US20060115449A1 (en) 2004-11-30 2006-06-01 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings
US7604818B2 (en) 2004-12-22 2009-10-20 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrocarbon monomers
WO2006066572A2 (en) 2004-12-22 2006-06-29 Gumlink A/S Biodegradable chewing gum comprising biodegradable polymer with high glass transition temperature
US8007775B2 (en) 2004-12-30 2011-08-30 Advanced Cardiovascular Systems, Inc. Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
US20060147491A1 (en) 2005-01-05 2006-07-06 Dewitt David M Biodegradable coating compositions including multiple layers
US20060198868A1 (en) 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
US7202325B2 (en) 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
KR100511618B1 (en) 2005-01-17 2005-08-24 이경범 Multi-layer coating of drug release controllable coronary stent and method for manufacturing the same
US20060240078A1 (en) 2005-03-24 2006-10-26 Clemson University Feed supplement delivery system
US20060224226A1 (en) 2005-03-31 2006-10-05 Bin Huang In-vivo radial orientation of a polymeric implantable medical device
US7842261B2 (en) 2005-04-21 2010-11-30 Purac Biochem Bv Process for preparing resorbable polyesters by bulk polymerization
US8778375B2 (en) * 2005-04-29 2014-07-15 Advanced Cardiovascular Systems, Inc. Amorphous poly(D,L-lactide) coating
WO2006135479A3 (en) 2005-05-10 2007-04-12 Angiotech Int Ag Anti-scarring agents, therapeutic compositions, and use thereof
US7291166B2 (en) * 2005-05-18 2007-11-06 Advanced Cardiovascular Systems, Inc. Polymeric stent patterns
US20060271170A1 (en) 2005-05-31 2006-11-30 Gale David C Stent with flexible sections in high strain regions
DE602005019546D1 (en) 2005-06-03 2010-04-08 Univ Twente Branched polymers, a macromonomer, process for their preparations and uses thereof
US20060276345A1 (en) 2005-06-07 2006-12-07 Halliburton Energy Servicers, Inc. Methods controlling the degradation rate of hydrolytically degradable materials
US7655584B2 (en) 2005-07-29 2010-02-02 Gore Enterprise Holdings, Inc. Highly porous self-cohered web materials
US7914574B2 (en) 2005-08-02 2011-03-29 Reva Medical, Inc. Axially nested slide and lock expandable device
WO2007019439A3 (en) 2005-08-04 2007-05-03 Angiotech Int Ag Block copolymer compositions and uses thereof
US7905021B2 (en) 2005-08-10 2011-03-15 Kamran Shirazi International dining kit
US20070034615A1 (en) 2005-08-15 2007-02-15 Klaus Kleine Fabricating medical devices with an ytterbium tungstate laser
US7476245B2 (en) 2005-08-16 2009-01-13 Advanced Cardiovascular Systems, Inc. Polymeric stent patterns
US20070208134A1 (en) 2005-10-03 2007-09-06 Hunter William L Anti-scarring drug combinations and use thereof
US20070087033A1 (en) 2005-10-14 2007-04-19 Sigg Daniel C Self-fixating scaffolds
DE102005056529A1 (en) 2005-11-28 2007-05-31 Mnemoscience Gmbh Compressible tubular material support or stent for insertion into vessels to be supported has tube folded one or more times in its longitudinal axis in temporary form of shape memory material
DE102005056532A1 (en) 2005-11-28 2007-05-31 Mnemoscience Gmbh Method for removal of tubular tissue supports e.g. stents from human or animal hollow organs, involves heating of tissue support to temperature below transition temperature, till softening
DE602006020063D1 (en) 2005-12-07 2011-03-24 Univ Ramot Drug-dispensing composite body
US20070149640A1 (en) 2005-12-28 2007-06-28 Sasa Andjelic Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates
US7902303B2 (en) 2005-12-30 2011-03-08 Industrial Technology Research Institute Aliphatic polyester polymer compositions and preparation method thereof
US20070151961A1 (en) 2006-01-03 2007-07-05 Klaus Kleine Fabrication of an implantable medical device with a modified laser beam
EP1976460A4 (en) 2006-01-19 2012-06-20 Warsaw Orthopedic Inc Injectable and moldable bone substitute materials
WO2007084609A3 (en) 2006-01-19 2008-01-24 Osteotech Inc Porous osteoimplant
FI20060077A (en) 2006-01-26 2007-07-27 Seppaelae Jukka Veli New biodegradable polymers
WO2007092559A3 (en) 2006-02-08 2008-02-21 Univ Northwestern A poly (diol-co-citrate) hydroxyapatite composite for tissue engineering and orthopaedic fixation devices
US7964210B2 (en) 2006-03-31 2011-06-21 Abbott Cardiovascular Systems Inc. Degradable polymeric implantable medical devices with a continuous phase and discrete phase
US8652192B2 (en) 2006-03-31 2014-02-18 St. Jude Medical, Cardiology Division, Inc. Stent and system and method for deploying a stent
US20070231362A1 (en) 2006-04-04 2007-10-04 3M Innovative Properties Company Schistose microfibrillated article for cell growth
US20070238167A1 (en) 2006-04-04 2007-10-11 3M Innovative Properties Company Flat microfibers as matrices for cell growth
EP2007317A2 (en) 2006-04-05 2008-12-31 University Of Nebraska Bioresorbable polymer reconstituted bone and methods of formation thereof
US8350087B2 (en) 2006-04-12 2013-01-08 Agency For Science, Technology And Research Biodegradable thermogelling polymer
US20070254012A1 (en) 2006-04-28 2007-11-01 Ludwig Florian N Controlled degradation and drug release in stents
US8747878B2 (en) 2006-04-28 2014-06-10 Advanced Cardiovascular Systems, Inc. Method of fabricating an implantable medical device by controlling crystalline structure
US8486135B2 (en) 2006-06-01 2013-07-16 Abbott Cardiovascular Systems Inc. Implantable medical devices fabricated from branched polymers
US7846361B2 (en) * 2006-07-20 2010-12-07 Orbusneich Medical, Inc. Bioabsorbable polymeric composition for a medical device
US8460362B2 (en) * 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
CN103494661B (en) * 2006-07-20 2016-03-30 奥巴斯尼茨医学公司 Bioabsorbable polymeric medical
US7959942B2 (en) * 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating

Also Published As

Publication number Publication date Type
WO2008070304A2 (en) 2008-06-12 application
CN101631513B (en) 2013-06-05 grant
US8691321B2 (en) 2014-04-08 grant
EP2073754A4 (en) 2012-09-26 application
WO2008070304A9 (en) 2008-07-31 application
EP2073754A2 (en) 2009-07-01 application
US20150028513A1 (en) 2015-01-29 application
CN101631513A (en) 2010-01-20 application
WO2008070304A3 (en) 2008-09-18 application
US9724864B2 (en) 2017-08-08 grant
CN103212115A (en) 2013-07-24 application
US20080206440A1 (en) 2008-08-28 application
CN103212115B (en) 2016-09-14 grant

Similar Documents

Publication Publication Date Title
US7416559B2 (en) Micromantled drug-eluting stent
US6652575B2 (en) Stent with smooth ends
Venkatraman et al. Implanted cardiovascular polymers: Natural, synthetic and bio-inspired
US20020165601A1 (en) Bioabsorbable stent-graft and covered stent
US20110190872A1 (en) Crush Recoverable Polymer Scaffolds Having a Low Crossing Profile
US20050021131A1 (en) Polymeric stent and method of manufacture
US20130150943A1 (en) Biodegradable endoprostheses and methods for their fabrication
US20100241214A1 (en) Optimized stent jacket
US20100016940A1 (en) Biodegradable self-expanding prosthesis
US7618448B2 (en) Polymeric, degradable drug-eluting stents and coatings
US6350277B1 (en) Stents with temporary retaining bands
US20060026815A1 (en) Slide and lock stent and method of manufacture from a single piece shape
US20080015686A1 (en) Controlled degradation of stents
US20040249450A1 (en) Stent and method of manufacturing stent
US20130331927A1 (en) Biodegradable endoprosthesis and methods for their fabrication
US20090182404A1 (en) Biodegradable self-expanding drug-eluting prosthesis
US20060025852A1 (en) Bioabsorbable self-expanding endolumenal devices
US6878160B2 (en) Stent with controlled expansion
US20070129789A1 (en) Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20070123977A1 (en) Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20070203564A1 (en) Biodegradable implants having accelerated biodegradation properties in vivo
US20080097580A1 (en) Morphological structures for polymeric drug delivery devices
US20080051875A1 (en) Bioabsorbable Polymeric Medical Device
US20070038292A1 (en) Bio-absorbable stent
US20070141107A1 (en) Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device

Legal Events

Date Code Title Description
AS Assignment

Owner name: ORBUSNEICH MEDICAL, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COTTONE, ROBERT J.;THATCHER, G. LAWRENCE;SIGNING DATES FROM 20071130 TO 20161106;REEL/FRAME:045955/0796